32776-21-9

Usage

Uses

Used in Pharmaceutical Synthesis:
N-ETHYL-2-PIPERIDIN-1-YLETHANAMINE is used as a building block for the synthesis of various pharmaceutical drugs and organic compounds. Its unique structure allows it to be incorporated into a wide range of molecules, contributing to the development of new medications and therapeutic agents.
Used in Medicinal Chemistry:
Due to its potential applications in medicinal chemistry, N-ETHYL-2-PIPERIDIN-1-YLETHANAMINE is utilized in the research and development of new drugs. Its ability to form stable complexes and interact with biological targets makes it a valuable tool in the design and synthesis of novel pharmaceuticals.
Used in Coordination Chemistry:
N-ETHYL-2-PIPERIDIN-1-YLETHANAMINE can also act as a ligand in coordination chemistry. This application allows it to form complexes with metal ions, which can be used in various chemical processes and as catalysts for specific reactions.
Used in Chemical Research:
N-ETHYL-2-PIPERIDIN-1-YLETHANAMINE's structural and functional properties make it a valuable asset in chemical research. N-ETHYL-2-PIPERIDIN-1-YLETHANAMINE is employed in studies aimed at understanding the properties of piperidine derivatives and their potential applications in various fields, including materials science and catalysis.

InChI:InChI=1/C9H20N2/c1-2-10-6-9-11-7-4-3-5-8-11/h10H,2-9H2,1H3

Upstream product

• 2008-75-5 N-chloroethylpiperidine hydrochloride 
• 75-04-7 ethylamine 
• 1932-03-2 2-(piperidin-4-yl)ethyl chloride 
• 27578-60-5 1-(2-aminoethyl)piperidine 
• 110-89-4 piperidine 

Downstream Products

• 1030630-18-2 N-ethyl-N-(2-piperidin-1-ylethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide 
• 1030630-44-4 C₁₈H₂₅F₃N₂O₂ 
• 1030630-31-9 N-ethyl-N-(2-piperidin-1-ylethyl)-2-[(2-trifluoromethoxy)phenyl]acetamide 

Relevant academic research and scientific papers

Novel analogs of the σ receptor ligand BD1008 attenuate cocaine-induced toxicity in mice

Previous studies have shown that BD1008 (N-[2-(3,4-dichlorophenyl)ethyl]-N- methyl-2-(1-pyrrolidinyl)ethylamine) and related analogs attenuate the toxicity and stimulant effects of cocaine through antagonism of σ receptors. In the present study, six analogs of BD1008 (UMB 98-103) were synthesized and evaluated in receptor binding and behavioral studies. Competition binding studies confirmed that all six compounds have high affinity for σ1 receptors, moderate affinity for σ2 receptors, and low to negligible affinity for monoamine transporters, opioid, N-methyl-D-aspartate, dopamine, and 5-HT receptors. In behavioral pharmacological studies, pretreatment of mice with UMB 100, UMB 101, or UMB 103 significantly attenuated cocaine-induced convulsions and lethality. Together with earlier studies, the data suggest that analogs of BD1008 are promising medication development leads for reducing the toxicity of cocaine.

Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites

A series of 1-phenyl-2-cyclopropylmethylamines structurally related to (+)- and (-)-MPCB were synthesized and their binding affinities for σ1, σ2, opioid and dopamine (D2) receptors were evaluated. Substitution of the cis-N-normetazocine with different aminic moieties provided compounds with high affinity and selectivity for σ binding sites with respect to opioid and dopamine (D2) receptors. The observed increase in σ2 affinity as compared to the parent (+)-MPCB, supports the idea that the particular stereochemistry of (+)-cis-N-normetazocine affects σ1 selectivity but does not affect σ1 affinity. The (±)-cis isomers of methyl 2-[(1-adamantylamino)methyl]-1-phenylcyclopropane-1-carboxylate (18) displayed a higher affinity and selectivity for the σ1 and σ2 receptor subtypes compared to the (±)-trans 19. Interestingly, the enantiomer (-)-cis 18 displayed a preference for σ1 receptor subtype whereas the (+)-cis 18 did for σ2. These results prompt us to synthesize compounds with modification of nitrogen and carboxyl groups. The compounds obtained showed high affinities and selectivity for σ sites. Moreover, modifications of carboxyl groups provided compounds with the highest affinities in the series. In particular, compound 25 with reverse-type ester showed a K(i) of 0.6 and 4.05nM for σ1 and σ2 binding sites, respectively. Copyright (C) 2000 Elsevier Science Ltd.

Alkylenediamine derivative anti-ulcer drug and antibacterial drug

The invention provides a compound which has anti-ulcer effect and antibacterial activity against Helicobacter pyroli. This compound is an alkylenediamine derivative or salt which has a general formula of (1): STR1 wherein each of R4, R5/s

Synthesis of novel succinamide derivatives having the 5,11-dihydro-6h- pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. I

A series of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one derivatives containing the succinamide skeleton has been synthesized and evaluated for M1, M2 and M3 muscarinic receptor binding affinities (in vitro) and M2 and M3 muscarinic receptor antagonistic activities (in vivo). Some of them showed higher and more selective binding affinities for M2 muscarinic receptors than that of AF-DX 116. Among them, 11-[3-[N-[2-(N- benzyl-N-methylamino)ethyl]-N-ethylearbamoyl]propionyl]-5,11-dihydro-6H- pyrido[2,3-b][1,4]benzodiazepin-6-one (68) was found to be the most potent and selective M2 muscarinic receptor antagonist in vitro. This compound also strongly inhibited the oxotremorine-induced bradycardia after intravenous administration and showed 130-fold selectivity for M2 muscarinic receptors over M3 muscarinic receptors in vivo.